Metsera responds to Pfizer litigation amid competing acquisition bids

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/20/2026

1. NVDA
2. CRWV
3. SPY
4. IRON
5. EYPT
6. TSLA
7. SLN
8. SLGN
9. STLD
10. CHRD

Go back to Metsera responds to Pfizer litigation amid competing acquisition bids

Metsera Issues Statement in Response to Litigation

November 3, 2025 11:02 AM EST

NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:

"Pfizer is trying to litigate its way to buying Metsera for a lower price than Novo Nordisk. Metsera's Board of Directors will continue to stand firm on behalf of shareholders and patients. Pfizer's litigation arguments are nonsense, and Metsera will address them in court."

... More